The new drug development in MBC focuses primarily on early-mid stage clinical trials of projects that MBC owns sole or partial commercialization rights. The core competency of MBC te......
more

  Molecular diagnostics is the leading growing segment within the in vitro diagnostics (IVD) market. The anticipated annual growth rate of molecular diagnostics segment is 15.3%, with ......
more

1. 2009-01-12
2. Medigen receives ASHI laboratory accreditation for HLA typing, a Taiwan first

1. 2009-01-01
2. Medigen Biotechnology Corporation now ASHI laboratory accredited for HLA typing (NEW)

1. 2008-12-28
2. Medigen Biotech Holds the “Cross-strait Bilateral Bioproducts Business Symposium”...

1. 2008-12-08
2. Medigen Biotech Signs an Agreement with CDC (Center for Disease Control) of Department of Health...

1. 2008-10-27
2. Medigen Enters Into a Letter of Intent With Pacgen Biotech in Canada

1. 2008-10-03
2. Medigen Biotech Received Top Innovation Award by the Ministry of Economic Affairs (MOEA), Taiwan

1. 2008-03-17
2. Oncolys BioPharma Ties Up with Medigen Biotech. For Telomelysin

1. 2008-03-05
2. Oncolys BioPharma and Medigen Biotechnology Enter Strategic Alliance and Licensing Agreement

1. 2007-11-28
2. [Announcment] MBC Collaborates with Academia Sinica for Liver Cancer Development

1. 2007-10-17
2. MBC Co-ops with NTU for New Drug Development

1. 2007-09-03
2. Tetralogy of Complementary Double-Core Business Model

1. 2007-08-06
2. MBC Enters Blood Screening Market in China

1. 2007-07-09
2. Taiwanese Bid for Anti-Cancer Drug

1. 2007-07-02
2. Big Pharmas Favor BioMed-Industry in Taiwan

1. 2007-06-16
2. New Drug PI-88 Decreases Liver Cancer Recurrence to 34%

1. 2007-06-15
2. Liver Cancer Treatment Breakthrough by PI-88 Phase II Trial

1. 2007-04-24
2. New Drug PI-88 Prevents Liver Cancer Recurrence

1. 2007-01-17
2. MBC to Profit from PI-88 Ahead of Time